{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:24:53Z","timestamp":1785788693373,"version":"3.56.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T00:00:00Z","timestamp":1646265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T00:00:00Z","timestamp":1646265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["NRF-2017R1E1A1A01074299"],"award-info":[{"award-number":["NRF-2017R1E1A1A01074299"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["2016R1A5A1007318"],"award-info":[{"award-number":["2016R1A5A1007318"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["NRF-2021R1A2C3011211"],"award-info":[{"award-number":["NRF-2021R1A2C3011211"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>BCR-ABL-independent drug resistance is a barrier to curative treatment of chronic myeloid leukemia (CML). However, the molecular pathways underlying BCR-ABL-independent tyrosine kinase inhibitor (TKI) resistance remain unclear.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In silico bioinformatic analysis was performed to identify the most active transcription factor and its inducer that contribute to BCR-ABL-independent TKI resistance. Tandem mass spectrometry analysis was performed to identify the receptor for the noncanonical NF-\u03baB activator FAM167A. In vitro and in vivo mouse experiments revealed detailed molecular insights into the functional role of the FAM167A-desmoglein-1 (DSG1) axis in BCL-ABL-independent TKI resistance. CML cells derived from CML patients were analyzed using quantitative reverse transcription PCR and flow cytometry.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We found that NF-\u03baB had the greatest effect on differential gene expression of BCR-ABL-independent TKI-resistant CML cells. Moreover, we found that the previously uncharacterized protein FAM167A activates the noncanonical NF-\u03baB pathway and induces BCR-ABL-independent TKI resistance. Molecular analyses revealed that FAM167A activates the noncanonical NF-\u03baB pathway by binding to the cell adhesion protein DSG1 to upregulate NF-\u03baB-inducing kinase (NIK) by blocking its ubiquitination. Neutralization of FAM167A in a mouse tumor model reduced noncanonical NF-\u03baB activity and restored sensitivity of cells to TKIs. Furthermore, FAM167A and surface DSG1 levels were highly upregulated in CD34<jats:sup>+<\/jats:sup> CML cells from patients with BCR-ABL-independent TKI-resistant disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>These results reveal that FAM167A acts as an essential factor for BCR-ABL-independent TKI resistance in CML by activating the noncanonical NF-\u03baB pathway. In addition, FAM167A may serve as an important target and biomarker for BCR-ABL-independent TKI resistance.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13046-022-02298-1","type":"journal-article","created":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T09:03:12Z","timestamp":1646298192000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["FAM167A is a key molecule to induce BCR-ABL-independent TKI resistance in CML via noncanonical NF-\u03baB signaling activation"],"prefix":"10.1186","volume":"41","author":[{"given":"Taewoo","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyu-Young","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwang-Hoon","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Sook","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeoung-Joon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Gyoo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,3]]},"reference":[{"issue":"8","key":"2298_CR1","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1073\/pnas.0510423103","volume":"103","author":"JP Radich","year":"2006","unstructured":"Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A. 2006;103(8):2794\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2298_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrm1280","volume":"5","author":"O Hantschel","year":"2004","unstructured":"Hantschel O, Superti-Furga G. Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol Cell Biol. 2004;5(1):33\u201344.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"11","key":"2298_CR3","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O'Brien","year":"2003","unstructured":"O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994\u20131004.","journal-title":"N Engl J Med"},{"issue":"14","key":"2298_CR4","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031\u20137.","journal-title":"N Engl J Med"},{"issue":"5","key":"2298_CR5","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2(5):561\u20136.","journal-title":"Nat Med"},{"issue":"8","key":"2298_CR6","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrc3317","volume":"12","author":"T O'Hare","year":"2012","unstructured":"O'Hare T, Zabriskie MS, Eiring AM, Deininger MW. Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer. 2012;12(8):513\u201326.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"2298_CR7","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","volume":"110","author":"T O'Hare","year":"2007","unstructured":"O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood. 2007;110(7):2242\u20139.","journal-title":"Blood"},{"issue":"3","key":"2298_CR8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3324\/haematol.2010.039560","volume":"96","author":"MS Mathisen","year":"2011","unstructured":"Mathisen MS, Kantarjian HM, Cortes J, Jabbour E. Mutant BCR-ABL clones in chronic myeloid leukemia. Haematologica. 2011;96(3):347\u20139.","journal-title":"Haematologica"},{"issue":"5","key":"2298_CR9","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","volume":"118","author":"S Soverini","year":"2011","unstructured":"Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011;118(5):1208\u201315.","journal-title":"Blood"},{"issue":"3","key":"2298_CR10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/nrclinonc.2016.139","volume":"14","author":"G Rosti","year":"2017","unstructured":"Rosti G, Castagnetti F, Gugliotta G, Baccarani M. Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom? Nat Rev Clin Oncol. 2017;14(3):141\u201354.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"2298_CR11","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","volume":"37","author":"TP Braun","year":"2020","unstructured":"Braun TP, Eide CA, Druker BJ. Response and resistance to BCR-ABL1-targeted therapies. Cancer Cell. 2020;37(4):530\u201342.","journal-title":"Cancer Cell"},{"issue":"12","key":"2298_CR12","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","volume":"129","author":"TL Holyoake","year":"2017","unstructured":"Holyoake TL, Vetrie D. The chronic myeloid leukemia stem cell: stemming the tide of persistence. Blood. 2017;129(12):1595\u2013606.","journal-title":"Blood"},{"issue":"4","key":"2298_CR13","doi-asserted-by":"publisher","first-page":"a000034","DOI":"10.1101\/cshperspect.a000034","volume":"1","author":"A Oeckinghaus","year":"2009","unstructured":"Oeckinghaus A, Ghosh S. The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol. 2009;1(4):a000034.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2298_CR14","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1146\/annurev.immunol.021908.132641","volume":"27","author":"S Vallabhapurapu","year":"2009","unstructured":"Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol. 2009;27:693\u2013733.","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"2298_CR15","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.cell.2004.07.013","volume":"118","author":"FR Greten","year":"2004","unstructured":"Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004;118(3):285\u201396.","journal-title":"Cell"},{"issue":"7007","key":"2298_CR16","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nature02924","volume":"431","author":"E Pikarsky","year":"2004","unstructured":"Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431(7007):461\u20136.","journal-title":"Nature"},{"issue":"5","key":"2298_CR17","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nri.2017.142","volume":"18","author":"K Taniguchi","year":"2018","unstructured":"Taniguchi K, Karin M. NF-kappaB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol. 2018;18(5):309\u201324.","journal-title":"Nat Rev Immunol"},{"issue":"18","key":"2298_CR18","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1101\/gad.1228704","volume":"18","author":"MS Hayden","year":"2004","unstructured":"Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev. 2004;18(18):2195\u2013224.","journal-title":"Genes Dev"},{"issue":"3","key":"2298_CR19","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.cell.2008.01.020","volume":"132","author":"MS Hayden","year":"2008","unstructured":"Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell. 2008;132(3):344\u201362.","journal-title":"Cell"},{"issue":"2","key":"2298_CR20","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S1097-2765(01)00187-3","volume":"7","author":"G Xiao","year":"2001","unstructured":"Xiao G, Harhaj EW, Sun SC. NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100. Mol Cell. 2001;7(2):401\u20139.","journal-title":"Mol Cell"},{"issue":"5534","key":"2298_CR21","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1126\/science.1062677","volume":"293","author":"U Senftleben","year":"2001","unstructured":"Senftleben U, Cao Y, Xiao G, Greten FR, Krahn G, Bonizzi G, et al. Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science. 2001;293(5534):1495\u20139.","journal-title":"Science"},{"issue":"1","key":"2298_CR22","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/cr.2010.177","volume":"21","author":"SC Sun","year":"2011","unstructured":"Sun SC. Non-canonical NF-kappaB signaling pathway. Cell Res. 2011;21(1):71\u201385.","journal-title":"Cell Res"},{"issue":"1","key":"2298_CR23","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.1600-065X.2011.01088.x","volume":"246","author":"SC Sun","year":"2012","unstructured":"Sun SC. The noncanonical NF-kappaB pathway. Immunol Rev. 2012;246(1):125\u201340.","journal-title":"Immunol Rev"},{"issue":"1","key":"2298_CR24","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/sj.leu.2403998","volume":"20","author":"D Cilloni","year":"2006","unstructured":"Cilloni D, Messa F, Arruga F, Defilippi I, Morotti A, Messa E, et al. The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance. Leukemia. 2006;20(1):61\u20137.","journal-title":"Leukemia"},{"issue":"7","key":"2298_CR25","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1038\/leu.2017.107","volume":"31","author":"SH Han","year":"2017","unstructured":"Han SH, Kim SH, Kim HJ, Lee Y, Choi SY, Park G, et al. Cobll1 is linked to drug resistance and blastic transformation in chronic myeloid leukemia. Leukemia. 2017;31(7):1659.","journal-title":"Leukemia"},{"issue":"3","key":"2298_CR26","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/35043032","volume":"1","author":"KJ Green","year":"2000","unstructured":"Green KJ, Gaudry CA. Are desmosomes more than tethers for intermediate filaments? Nat Rev Mol Cell Biol. 2000;1(3):208\u201316.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"2298_CR27","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1172\/JCI69071","volume":"123","author":"CM Hammers","year":"2013","unstructured":"Hammers CM, Stanley JR. Desmoglein-1, differentiation, and disease. J Clin Invest. 2013;123(4):1419\u201322.","journal-title":"J Clin Invest"},{"issue":"11","key":"2298_CR28","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1038\/sj.jid.5701015","volume":"127","author":"KJ Green","year":"2007","unstructured":"Green KJ, Simpson CL. Desmosomes: new perspectives on a classic. J Invest Dermatol. 2007;127(11):2499\u2013515.","journal-title":"J Invest Dermatol"},{"issue":"6","key":"2298_CR29","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872\u201384.","journal-title":"Blood"},{"issue":"7","key":"2298_CR30","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1053\/j.gastro.2005.03.002","volume":"128","author":"SG Park","year":"2005","unstructured":"Park SG, Ryu HM, Lim SO, Kim YI, Hwang SB, Jung G. Interferon-gamma inhibits hepatitis B virus-induced NF-kappaB activation through nuclear localization of NF-kappaB-inducing kinase. Gastroenterology. 2005;128(7):2042\u201353.","journal-title":"Gastroenterology"},{"issue":"2","key":"2298_CR31","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/ni.1687","volume":"10","author":"SG Park","year":"2009","unstructured":"Park SG, Schulze-Luehrman J, Hayden MS, Hashimoto N, Ogawa W, Kasuga M, et al. The kinase PDK1 integrates T cell antigen receptor and CD28 coreceptor signaling to induce NF-kappaB and activate T cells. Nat Immunol. 2009;10(2):158\u201366.","journal-title":"Nat Immunol"},{"issue":"5663","key":"2298_CR32","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1126\/science.1094351","volume":"303","author":"D Zhang","year":"2004","unstructured":"Zhang D, Zhang G, Hayden MS, Greenblatt MB, Bussey C, Flavell RA, et al. A toll-like receptor that prevents infection by uropathogenic bacteria. Science. 2004;303(5663):1522\u20136.","journal-title":"Science"},{"issue":"4","key":"2298_CR33","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1172\/JCI65220","volume":"123","author":"RM Harmon","year":"2013","unstructured":"Harmon RM, Simpson CL, Johnson JL, Koetsier JL, Dubash AD, Najor NA, et al. Desmoglein-1\/Erbin interaction suppresses ERK activation to support epidermal differentiation. J Clin Invest. 2013;123(4):1556\u201370.","journal-title":"J Clin Invest"},{"issue":"9","key":"2298_CR34","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/nri.2017.52","volume":"17","author":"SC Sun","year":"2017","unstructured":"Sun SC. The non-canonical NF-kappaB pathway in immunity and inflammation. Nat Rev Immunol. 2017;17(9):545\u201358.","journal-title":"Nat Rev Immunol"},{"issue":"25","key":"2298_CR35","doi-asserted-by":"publisher","first-page":"26243","DOI":"10.1074\/jbc.M403286200","volume":"279","author":"G Liao","year":"2004","unstructured":"Liao G, Zhang M, Harhaj EW, Sun SC. Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J Biol Chem. 2004;279(25):26243\u201350.","journal-title":"J Biol Chem"},{"issue":"18","key":"2298_CR36","doi-asserted-by":"publisher","first-page":"11704","DOI":"10.1074\/jbc.M114.635086","volume":"290","author":"B Jiang","year":"2015","unstructured":"Jiang B, Shen H, Chen Z, Yin L, Zan L, Rui L. Carboxyl terminus of HSC70-interacting protein (CHIP) down-regulates NF-kappaB-inducing kinase (NIK) and suppresses NIK-induced liver injury. J Biol Chem. 2015;290(18):11704\u201314.","journal-title":"J Biol Chem"},{"issue":"1","key":"2298_CR37","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/path.4502","volume":"236","author":"S Yao","year":"2015","unstructured":"Yao S, Zheng P, Wu H, Song LM, Ying XF, Xing C, et al. Erbin interacts with c-Cbl and promotes tumourigenesis and tumour growth in colorectal cancer by preventing c-Cbl-mediated ubiquitination and down-regulation of EGFR. J Pathol. 2015;236(1):65\u201377.","journal-title":"J Pathol"},{"issue":"11","key":"2298_CR38","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1038\/ng.2792","volume":"45","author":"CJ Lessard","year":"2013","unstructured":"Lessard CJ, Li H, Adrianto I, Ice JA, Rasmussen A, Grundahl KM, et al. Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjogren's syndrome. Nat Genet. 2013;45(11):1284\u201392.","journal-title":"Nat Genet"},{"issue":"12","key":"2298_CR39","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1136\/annrheumdis-2018-213634","volume":"77","author":"LA Aqrawi","year":"2018","unstructured":"Aqrawi LA, Mentlein L, Meneghel L, Bjork A, Thorlacius GE, Ivanchenko M, et al. Clinical associations and expression pattern of the autoimmunity susceptibility factor DIORA-1 in patients with primary Sjogren's syndrome. Ann Rheum Dis. 2018;77(12):1840\u20132.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"2298_CR40","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1056\/NEJMoa0707865","volume":"358","author":"G Hom","year":"2008","unstructured":"Hom G, Graham RR, Modrek B, Taylor KE, Ortmann W, Garnier S, et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med. 2008;358(9):900\u20139.","journal-title":"N Engl J Med"},{"issue":"2","key":"2298_CR41","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/art.24246","volume":"60","author":"I Ito","year":"2009","unstructured":"Ito I, Kawasaki A, Ito S, Hayashi T, Goto D, Matsumoto I, et al. Replication of the association between the C8orf13-BLK region and systemic lupus erythematosus in a Japanese population. Arthritis Rheum. 2009;60(2):553\u20138.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"2298_CR42","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1002\/art.30563","volume":"63","author":"E Sanchez","year":"2011","unstructured":"Sanchez E, Comeau ME, Freedman BI, Kelly JA, Kaufman KM, Langefeld CD, et al. Identification of novel genetic susceptibility loci in African American lupus patients in a candidate gene association study. Arthritis Rheum. 2011;63(11):3493\u2013501.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2298_CR43","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jaut.2009.08.014","volume":"34","author":"P Gourh","year":"2010","unstructured":"Gourh P, Agarwal SK, Martin E, Divecha D, Rueda B, Bunting H, et al. Association of the C8orf13-BLK region with systemic sclerosis in north-American and European populations. J Autoimmun. 2010;34(2):155\u201362.","journal-title":"J Autoimmun"},{"issue":"3","key":"2298_CR44","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1002\/art.27303","volume":"62","author":"I Ito","year":"2010","unstructured":"Ito I, Kawaguchi Y, Kawasaki A, Hasegawa M, Ohashi J, Kawamoto M, et al. Association of the FAM167A-BLK region with systemic sclerosis. Arthritis Rheum. 2010;62(3):890\u20135.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"2298_CR45","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1002\/art.30379","volume":"63","author":"B Coustet","year":"2011","unstructured":"Coustet B, Dieude P, Guedj M, Bouaziz M, Avouac J, Ruiz B, et al. C8orf13-BLK is a genetic risk locus for systemic sclerosis and has additive effects with BANK1: results from a large french cohort and meta-analysis. Arthritis Rheum. 2011;63(7):2091\u20136.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2298_CR46","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.jaci.2018.04.007","volume":"142","author":"L Polivka","year":"2018","unstructured":"Polivka L, Hadj-Rabia S, Bal E, Leclerc-Mercier S, Madrange M, Hamel Y, et al. Epithelial barrier dysfunction in desmoglein-1 deficiency. J Allergy Clin Immunol. 2018;142(2):702\u20136 e7.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"2298_CR47","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jid.2019.08.433","volume":"140","author":"E Cohen-Barak","year":"2020","unstructured":"Cohen-Barak E, Godsel LM, Koetsier JL, Hegazy M, Kushnir-Grinbaum D, Hammad H, et al. The role of Desmoglein 1 in gap junction turnover revealed through the study of SAM syndrome. J Invest Dermatol. 2020;140(3):556\u201367 e9.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"2298_CR48","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.tcb.2016.11.007","volume":"27","author":"C Rabouille","year":"2017","unstructured":"Rabouille C. Pathways of unconventional protein secretion. Trends Cell Biol. 2017;27(3):230\u201340.","journal-title":"Trends Cell Biol"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-022-02298-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-022-02298-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-022-02298-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T18:04:30Z","timestamp":1666289070000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-022-02298-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,3]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2298"],"URL":"https:\/\/doi.org\/10.1186\/s13046-022-02298-1","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,3]]},"assertion":[{"value":"7 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained in accordance with the Declaration of Helsinki, and all procedures were approved by the Institutional Review Board of Seoul National University (E2103\/003\u2013007) and the Gwangju Institute of Science and Technology (20180629-BR-36-01-02). Animal experiments were approved by Institutional Animal Care and Use Committees at Seoul National University (SNU-210315-6) and the Gwangju Institute of Science and Technology (GIST-2019-008).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"82"}}